Clinical trials: First Pregnancy
METASTATIC CERVICAL CANCER
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy…
- Trial name
- NCT05446883
- Testing
- QL1706, Paclitaxel injection, Cisplatin/Carboplatin
- Where
- 3 sites in China
- Volunteers
- 498 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Ovarian Cancer, Fallopian Tube Cancer
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma
- Trial name
- MAMOC (NCT04227522)
- Testing
- Rucaparib
- Where
- 17 sites in Germany
- Volunteers
- 42 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT06580314
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 695 sites in United States, Japan and 1 more
- Volunteers
- 880 people
- Sponsor
- NRG Oncology
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
The purpose of the protocol, is to describe the use of cabozantinib tablets as monotherapy or in combination with nivolumab including the number of dose reductions, dose interruptions and terminations due to (serious) adverse…
- Trial name
- CABOCARE (NCT03647878)
- Where
- 82 sites in Austria, Germany
- Volunteers
- 224 people
- Sponsor
- Ipsen
Maternal Care Patterns, Nutrition, Healthy
The 1000 First Day of Life : Effect of Multi Micronutrients Supplementation on Pregnancy Outcomes
To monitor the effects of multi micronutrients supplementations during pregnancy towards pregnancy outcomes
- Conditions
- Maternal Care Patterns, Nutrition, Healthy, Nutritional Deficiency, Maternal-Fetal Relations
- Trial name
- NCT06035315
- Testing
- Multiple Micronutrients during pregnancy
- Where
- 2 sites in Indonesia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2…
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian Cancer
- Trial name
- NCT07612891
- Testing
- INV-6452
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Metastatic Renal Cell Carcinoma ( mRCC)
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
To describe real-world demographic and clinical characteristics, treatment characteristics, and clinical outcomes among patients in Latin America who were treated with first-line sunitinib for metastatic renal cell carcinoma and…
- Trial name
- NCT04115189
- Testing
- Sunitinib
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 57 people
- Sponsor
- Pfizer
Pre-Eclampsia, Pregnancy Complications
Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy
Preeclampsia (PE) affects from 2 to 8% of pregnant women. Recent studies show that prevention is the best strategy to improve perinatal outcomes.
- Trial name
- CRISP (NCT04767438)
- Testing
- Pregnant women
- Volunteers
- 6,560 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Gestational Diabetes
miRNA (microRNA) and FGF21 (Fibroblast Growth Factor-21) Profile in First Trimester and Gestational Diabetes Prediction
The goal of this observational study is to compare miRNA and FGF21 in pregnancy with and without GDM (Gestational Diabetes) The main question it aims to answer that miRNA and FGF21 are different between two groups.
- Trial name
- NCT05632055
- Testing
- blood draw
- Where
- Thailand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
Threatened Miscarriage, Early Pregnancy Bleeding
Comparison of Dydrogesterone Alone Versus Dydrogesterone Plus HCG in Threatened Miscarriage
This randomized controlled trial aims to compare the efficacy of Dydrogesterone alone versus Dydrogesterone combined with human chorionic gonadotrophin (HCG) in the treatment of threatened miscarriage in first trimester…
- Trial name
- DYD-HCG (NCT07608133)
- Testing
- Dydrogesterone, Human chorionic gonadotrophin (hCG)
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Pakistan Air Force (PAF) Hospital Islamabad
Cervical Cancer
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer
To evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in first-line treatment of stage IIIC2 cervical cancer.
- Trial name
- NCT05511623
- Testing
- tislelizumab, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 112 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Ovarian Cancer
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006453
- Testing
- carboplatin, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada
- Sponsor
- AGO Study Group
Abortion in First Trimester
Choice of Modality of Follow up for Medication Abortion
This study will assess the impact of providing medication abortion-seeking clients a choice for follow-up in practice. Clients presenting at or less than 63 days pregnant (based on last menstrual period) at the study site for…
- Trial name
- NCT04056637
- Testing
- Choice of follow-up option, Multi-level pregnancy test
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Stanford University
Epithelial Ovarian Cancer
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
As < 10% of the necessary patients required by the protocol were recruited and the data were not intended to support a labeling claim, it was determined that the abbreviated clinical study report (CSR) was the appropriate…
- Trial name
- CANVAS (NCT01521143)
- Testing
- Cvac
- Where
- 8 sites in United States, Australia
- Volunteers
- 91 people
- Sponsor
- Prima BioMed Ltd
Postpartum Period, Pregnancy
Enhancing Care & Outcomes for Patients During the First Postpartum Year
The United States is in the midst of a maternal mortality and morbidity crisis, with more than half of maternal deaths occurring within the first postpartum year.
- Conditions
- Postpartum Period, Pregnancy, Hypertension, Pregnancy Induced
- Trial name
- NCT06615076
- Testing
- Postpartum Visits
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Maryland, Baltimore
Epithelial Ovarian Cancer
Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer
The purpose of this study is to determine if patients with p53 mutated epithelial ovarian cancer that have been treated with first line treatment (paclitaxel - carboplatin combination therapy) and that have shown early relapse…
- Trial name
- M10MKO (NCT01164995)
- Testing
- MK-1775 and carboplatin
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Ureter Cancer, Urethral Cancer
- Trial name
- NCT01191892
- Testing
- carboplatin, gemcitabine hydrochloride, vandetanib
- Where
- 21 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Cardiff University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.